What is Wegovy and how does it differ from Ozempic?
Wegovy and Ozempic both contain the same active ingredient, semaglutide, but they are licensed for different uses and dosed differently. Wegovy is the higher-dose product (up to 2.4mg weekly) TGA-approved for chronic weight management. Ozempic uses lower doses (up to 1.0mg weekly) and is TGA-approved for type 2 diabetes mellitus.
This regulatory distinction matters for the PBS. Australia's Pharmaceutical Benefits Scheme subsidises Ozempic under Authority Streamlined for diabetes patients meeting specific criteria. Wegovy, despite containing the same molecule, has no PBS listing. The result: a person paying $31.60/month for PBS Ozempic and a person paying $450/month for private Wegovy are taking essentially the same drug for similar purposes, at a 14x cost difference.
Why isn’t Wegovy on the PBS?
The Pharmaceutical Benefits Advisory Committee (PBAC) assesses every drug submission against clinical effectiveness and cost-effectiveness criteria. Wegovy submissions for PBS listing have previously been rejected, primarily on cost-effectiveness grounds, the budget impact of broadly subsidising a chronic obesity medication for the ~30% of Australian adults who meet the BMI threshold is substantial.
The Australian Institute of Health and Welfare estimates obesity-related conditions cost the healthcare system $11.8 billion annually. Advocates argue this justifies PBS subsidy; the PBAC's role is to weigh that argument against the upfront cost to the Federal budget. As of 2026, the calculus has not yet favoured listing.
PBAC submissions and outcomes are published on the Department of Health website. Watch for the quarterly meeting outcomes statements if you want to track potential listing changes.
What you’ll pay for Wegovy in 2026
| Pathway | Monthly cost | What’s included |
|---|---|---|
| Retail pharmacy + GP | $420–$530 | Medication only; GP consult fees separate ($80–$200/visit) |
| Telehealth bundle | $290–$450 | Medication + consultations + coaching all-inclusive |
| Specialist (endocrinologist) | $480–$600+ | Initial specialist consult $250–$450; medication retail price |
Telehealth bundle pricing varies by provider and dose. Higher maintenance doses (1.7mg, 2.4mg) sit at the top of each range. Compare your real cost in our GLP-1 switch cost calculator.
Don’t forget escalation: Wegovy titrates from 0.25mg through 0.5, 1.0, 1.7 and finally 2.4mg over 16-20 weeks. The lower-dose pens are typically the same price as higher-dose pens (manufacturer pricing is dose-flat), so your monthly cost is consistent throughout titration.
Who can be prescribed Wegovy in Australia?
TGA approval covers adults meeting either:
- BMI of 30 kg/m² or higher (obesity), or
- BMI of 27 kg/m² or higher with at least one weight-related comorbidity, type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.
Your prescriber documents your BMI calculation and any qualifying comorbidities. Pregnant women, breastfeeding mothers, people with a personal or family history of medullary thyroid carcinoma, and people with MEN 2 syndrome should not be prescribed Wegovy. People with active gallbladder disease, pancreatitis history or severe gastroparesis require careful consideration.
Wegovy vs the other GLP-1 options
For Australians paying privately, the practical comparison is usually Wegovy vs Mounjaro vs off-label Ozempic. Briefly:
- Wegovy. The on-label weight-loss option. Strong clinical evidence (STEP trials show ~15% weight loss over 68 weeks). Standard private pricing.
- Mounjaro (tirzepatide). Newer dual-agonist. Trials show different weight-change range in trials (~20% over 72 weeks). Typically $30-$80/month more expensive than Wegovy. Read our Mounjaro PBS coverage guide.
- Off-label Ozempic. Lower-dose semaglutide, prescribed off-label for weight loss. Marginally cheaper than Wegovy but not the on-label choice. Capped at 1.0mg dose (vs Wegovy 2.4mg) which limits efficacy.
- Saxenda (liraglutide). Daily injection. Largely superseded by weekly options. Some patients prefer the shorter half-life if managing side effects.
Could PBS listing for Wegovy happen in the future?
It’s possible but not imminent. The Royal Australasian College of Physicians and obesity medicine bodies continue to advocate for PBS subsidy. Future submissions to the PBAC are likely to focus on:
- Restricted populations (e.g., BMI ≥35 plus comorbidity, similar to bariatric surgery criteria)
- Risk-share agreements between Novo Nordisk and the Federal Government to cap budget exposure
- Stepped-care models requiring documented lifestyle intervention failure first
If you want to follow PBAC decisions, the public meeting outcomes are published on the Department of Health website after each quarterly meeting (March, July, November).
How to find a reputable Wegovy prescriber
Avoid clinics offering compounded semaglutide (often advertised as "weight loss injections at a fraction of the cost"). These are not TGA-assessed and the AHPRA medical board has issued cautions. Your Wegovy script should come from an AHPRA-registered GP, endocrinologist or obesity medicine physician, with baseline blood work and ongoing monitoring included.
Browse our independent directory of verified Australian weight loss clinics, filterable by services, location and prescriber type.
Related coverage
- Is Ozempic covered by PBS?the only GLP-1 with PBS pathway
- Is Mounjaro covered by PBS?tirzepatide subsidy status
- How Ozempic is prescribed off-label
- Wegovy cost hub, detailed pricing